Literature DB >> 8640346

Determination of KA values by controlled receptor expression in Xenopus oocytes.

H Murakoshi1, K Nunoki, K Ishii, N Taira.   

Abstract

1. In the present study we estimated the KA value of endothelin-1 (ET-1) for ETA-receptors by a new method in which the level of expression of ETA-receptors in Xenopus oocytes was altered in a controlled way. 2. Kvl.2 (a delayed rectifier type K channel) c RNA at the fixed concentration of 0.2 micro g micro l(-1) was mixed with ETA-receptor cRNA at various concentration ratios (10(-3)-3). Oocytes were examined 2-4 days after the injection of the cRNA mixtures. 3. In these oocytes, ET-1 suppressed the amplitude of Kvl.2 current in a dose-dependent manner in the range of 0.1-100 nM; the maximum inhibition produced by ET-1 was larger and the EC50 value for the inhibition by ET-1 was smaller as the mixture ratio was increased. Double-reciprocal plots of equiactive concentrations of ET-1 in 1/1- and 1/30-injected oocytes yielded a KA for ET-1 of 7.4 nM. The number of ETA-receptors in 1/30-injected oocytes was 13% of that in 1/1-injected oocytes, whereas the inhibition of the current in 1/30-injected oocytes was about 60% of that in 1/1-injected oocytes. This suggests the presence of spare receptors of ETA in the latter. 4. A saturation binding experiment estimated a KD value of 0.1 nM for ET-1 at ETA-receptors and the number of ETA-receptors in 1/30-injected oocytes was 23% of that in 1/1-injected ones. This value was not significantly different from that estimated by the above new method. However, there was a discrepancy between KA and KD, which could be due to factors unique to the expression system employed in the present study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8640346      PMCID: PMC1908941          DOI: 10.1111/j.1476-5381.1995.tb16412.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  A modification of receptor theory.

Authors:  R P STEPHENSON
Journal:  Br J Pharmacol Chemother       Date:  1956-12

Review 2.  Agonist potency and apparent affinity: interpretation using classical and steady-state ternary-complex models.

Authors:  D Mackay
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

3.  Interpretation of agonist affinity estimations: the question of distributed receptor states.

Authors:  J W Black; N P Shankley
Journal:  Proc R Soc Lond B Biol Sci       Date:  1990-06-22

Review 4.  Errors in agonist affinity estimation: do they and should they occur in isolated tissue experiments?

Authors:  P Leff; I G Dougall; D H Harper; I A Dainty
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

5.  A new method to estimate apparent dissociation constants for desensitizing agonists without using antagonists.

Authors:  R Morgenstern
Journal:  Acta Biol Med Ger       Date:  1974

6.  The determination of the histamine equilibrium constant for its receptor in the smooth muscle by changing the extracellular calcium concentration.

Authors:  J M Giad Rico
Journal:  Eur J Pharmacol       Date:  1971-10       Impact factor: 4.432

7.  Graphical and weighted regression analyses for the determination of agonist dissociation constants.

Authors:  C D Thron
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

8.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists.

Authors:  R B Parker; D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

9.  Differential capacity for translation and lack of competition between mRNAs that segregate to free and membrane-bound polysomes.

Authors:  J D Richter; L D Smith
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

10.  Application of the operational model of agonism to establish conditions when functional antagonism may be used to estimate agonist dissociation constants.

Authors:  P Leff; G R Martin; J M Morse
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.